PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals — Investor Presentation (May 2021)

30 slides from PhaseBio Pharmaceuticals's investor presentation, May 13, 2021

  1. Slide 1: Corporate Overview May 2021

    Corporate Overview May 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding future results of operations and financial position of PhaseBio Pharmaceuticals, Inc. (“we,” “us” or “our”), our business str

  3. Slide 3: Therapeutic Focus

    Therapeutic Focus Clinical-stage biopharma company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases Product Candidates Bentracimab (PB2452) Novel agent in Phase 3 development for immediate and sustained reversal of ticagrelor, the preferred antipl

  4. Slide 4: Pipeline programs and upcoming milestone targets

    Program Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Rights Upcoming Milestone Target2 Bentracimab Reversal of Ticagrelor Antiplatelet Activity Q2 2021 Publication of Phase 2a trial results Pemziviptadil Pulmonary Arterial Hypertension (PAH) 1H 20223 Report Phase 2b data PB6440 Resistant Hyperten

  5. Slide 5: Corporate

    ) Corporate

  6. Slide 6: Experienced Management Team

    6 Experienced Management Team JONATHAN MOW Chief Executive Officer SUSAN ARNOLD, PhD VP of Preclinical & CMC GLEN BURKHARDT VP Human Resources KRIS HANSON VP Legal JOHN LEE, MD, PhD, FACC Chief Medical Officer JOHN SHARP Chief Financial Officer MICHAEL YORK VP Corp Development & Commercial Strategy

  7. Slide 7: 2020 Was A Year of Substantial Progress

    • Rapid pace of development and execution in 2020, sets the stage for success in 2021  Announced innovative funding and co-development collaboration for bentracimab with SFJ Pharmaceuticals  Bolstered pipeline with acquisition of resistant hypertension asset, PB6440  Granted EMA PRIME designation

  8. Slide 8: Q1 2021 Financial Highlights

    • Operating expense: $25.6M ⎯ R&D: $22.3M ⎯ SG&A: $3.3M • Loss from Operations: ($25.6M) • Net Loss of ($27.4M) or ($0.87) per share ⎯ 31.3M shares used for computing Q1 2021 net loss per share • Cash and cash equivalents as of 03/31/2021: $77.0M • Available SFJ funding as of 03/31/2021: $27.7M Q1 2

  9. Slide 9: Bentracimab (PB2452) Reversal Agent for Ticagrelor

    Bentracimab (PB2452) Reversal Agent for Ticagrelor

  10. Slide 10: Bentracimab: urgent surgery or intervention

    Bentracimab 10 URGENT SURGERY OR INTERVENTION • Currently oral P2Y12 agents, including ticagrelor, require a 5-day washout prior to surgery1,2 ⎯ Urgent surgery often cannot wait 5 days ⎯ Higher thrombotic risk during washout • In Phase 1 and Phase 2a studies, bentracimab observed to immediately and

  11. Slide 11: Well-Characterized Mechanism of Reversal of Ticagrelor

    Bentracimab Bentracimab: Well-Characterized Mechanism of Reversal of Ticagrelor 11 1. 2. 3. 4. 5. 6. ADP binds to P2Y12 receptor causing platelet aggregation Ticagrelor binds to P2Y12, inhibiting ADP-induced platelet aggregation Bentracimab binds to free ticagrelor with very high affinity This is a

  12. Slide 12: Phase 1 Proof-of-Concept Study in Healthy Subjects

    Bentracimab Bentracimab Phase 1 Proof-of-Concept Study in Healthy Subjects • Randomized, double-blind, placebo-controlled, single ascending dose, sequential group study (n=64) • Platelet function evaluated using three well established and commonly used assays: LTA, VerifyNow PRUTest® and VASP ⎯ Resu

  13. Slide 13: Normalized Platelet Function After Ticagrelor Reversal

    Bentracimab  Dose-dependent response across all cohorts tested  Immediate reversal within 5 minutes of start of infusion  Sustained duration of reversal extended to 20+ hours  Enables rapid resumption of ticagrelor dosing post infusion  Well tolerated across all cohorts  No drug-related SAEs r

  14. Slide 14: Positive Preliminary Bentracimab Phase 2a Results

    Bentracimab Positive Preliminary Bentracimab Phase 2a Results • Positive preliminary results from the bentracimab Phase 2a trial were disclosed via press release1 ⎯ First trial of bentracimab to include older and elderly subjects (ages 50-80) on dual antiplatelet therapy (DAPT) of ticagrelor and low

  15. Slide 15: REVERSE-IT: Pivotal Phase 3 Trial Overview

    Bentracimab REVERSE-IT: Bentracimab Pivotal Phase 3 Trial Overview • REVERSE-IT: Rapid and SustainEd ReVERSal of TicagrElor – Intervention Trial • Phase 3 trial is a key element of development plan that has garnered FDA Breakthrough Therapy and EMA PRIME designations • Open-label, single-arm study o

  16. Slide 16: REVERSE-IT Enrollment Ahead of Original Projection

    bentracimab REVERSE-IT Enrollment Ahead of Original Projection 16 As of March 2021, REVERSE-IT had enrolled 60 of the first 100 patients for the Interim Analysis • Enrollment robust and ahead of initial projections despite COVID pandemic • Nearly all subjects enrolled to date required urgent surgery

  17. Slide 17: REVERSE-IT Predominance of Surgical Patients

    bentracimab REVERSE-IT Predominance of Surgical Patients 17 Pandemic impact on bleeding patient admissions • Reduction in hospital admissions for major adverse spontaneous events like bleeding • Broad, global moratorium on clinical research and furloughs of research staff • Smaller REVERSE-IT footpr

  18. Slide 18: Revised Timelines of Bentracimab Program

    bentracimab Revised Timelines of Bentracimab Program 18 2019 2020 2021 2022 2023 Phase 2B: 50-80 year old volunteersPhase 2APhase 1 NEJM FDA Breakthrough Therapy FDA EOP1 EMA PRIME Designation N=200, 150 randomized to receive PB2452 N=100, major bleeding + urgent surgery patients Final N=200 Post-ap

  19. Slide 19: EMA and FDA regulatory interactions

    bentracimab EMA: • Scientific Advice ⎯ Face-to-face interaction and written guidance in general agreement with proposed development plan for bentracimab • PRIME designation1 ⎯ Granted to support medicines that demonstrate the potential to address substantial unmet medical need ⎯ Potentially expedite

  20. Slide 20: Expect Continued Long-Term Rx Growth of Ticagrelor

    Bentracimab Expect Continued Long-Term Rx Growth of Ticagrelor Bentracimab approval has the potential to drive continued positive momentum • Brilinta/Brilique sales in 2020 were $1.6B and growing ⎯ Pandemic impact dampened 2020 growth ⎯ Patient growth remains a key driver of Y/Y revenue growth in ke

  21. Slide 21: SFJ Pharmaceuticals Funding and Co-Development Collaboration

    Bentracimab SFJ Pharmaceuticals Funding and Co-Development Collaboration • Innovative collaboration between SFJ and PhaseBio to support the global development of bentracimab • SFJ will fund up to $120 million to support the clinical development of bentracimab ⎯ SFJ has extensive experience in the gl

  22. Slide 22: Pemziviptadil (PB1046) Once Weekly VIP Analog

    Pemziviptadil (PB1046) Once Weekly Vasoactive Intestinal Peptide (VIP) Analog

  23. Slide 23: Harnessing VIP to Create a Stable, Long-Acting Drug

    Pemziviptadil PRECLINICAL STUDIES Support Clinical Development for: • Pulmonary Arterial Hypertension • DMD Cardiomyopathy • Heart Failure (Chemotherapy-Induced HF or HFpEF) • Cystic Fibrosis MECHANISM OF ACTION VIA VPAC2 RECEPTOR • Potent vasodilator and immunomodulator • Anti-inflammatory and anti

  24. Slide 24: Proprietary Elastin-Like Polypeptide (ELP) Technology

    Pemziviptadil PROLONGED CIRCULATING HALF-LIFE COACERVATION DELIVERS SLOW RELEASE Proprietary Elastin-Like Polypeptide (ELP) Technology Key to optimizing the profile of an injectable VIP product candidate 24 Repeating Sequence of Human Elastin Peptides VPGXG Peptide/Protein (VIP, GLP1, etc.) Active M

  25. Slide 25: High Unmet Need in an Orphan Disease

    Pemziviptadil High Unmet Need in an Orphan Disease Primary Pulmonary Arterial Hypertension (PAH, WHO Group 1 PH) • High unmet need for novel disease-modifying PAH therapies for greater efficacy ⎯ All 3 approved drug classes in PAH are vasodilators: prostacyclin, endothelin, and nitric oxide pathways

  26. Slide 26: Clinical Development Activities to Date

    Pemziviptadil Pemziviptadil Clinical Development Activities to Date Have Supported Advancement into Phase 2 Efficacy Studies 26 PHASE 1 Studies Completed PHASE 2 PAH Studies • Well tolerated for a week over broad range of exposure; no drug-related SAEs reported • Prolonged PK/PD profile over 1 week

  27. Slide 27: PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

    PB6440 Aldosterone Synthase Inhibitor for Resistant Hypertension

  28. Slide 28: PB6440 for Resistant Hypertension

    PB6440 PB6440 for Resistant Hypertension • Upwards of 10 million patients in the United States have resistant hypertension and are at risk for serious, costly medical consequences (stroke, heart attack, kidney failure, etc.)1 • Physicians currently prescribe numerous combinations of antihypertensive

  29. Slide 29: PB6440 Is Highly Selective for Aldosterone Synthase

    PB6440 CYP11B Potency and Selectivity (IC50, µM) Human Monkey CYP11B2 CYP11B1# Selectivity CYP11B2 CYP11B1 Selectivity PB6440 0.024 4.859 202 0.016 5.802 363 LCI699* 0.0007 0.013 19 0.016 0.059 3.7 PB6440 Is Highly Selective for Aldosterone Synthase (CYP11B2) Selectivity and Potency Demonstrated in

  30. Slide 30: PhaseBio

    PhaseBio

PhaseBio Pharmaceuticals — Investor Presentation (May 2021) on 6ix